Patients and carers

  • Email
  • Help

Information for you

On this page, you will find information on the Agency’s activities that are most relevant to patients and carers, including news, and events.

You can contribute to the Agency’s work by responding to public consultations.

Learn more about how Patients and carers are actively involved in the work of the Agency.

Featured information

  • Human medicines highlights for 2016

    EMA has released an overview of its key recommendations in 2016 on the authorisation of new medicines. EMA recommended 81 medicines for marketing authorisation. This includes recommendations for 27 new active substances.

  • pharmacovigilance icon

    Tenth stakeholder forum on pharmacovigilance legislation

    This forum brought together regulators with patients, healthcare professionals and industry, to take stock of what has been achieved and what needs to be the focus over the coming years. EMA has published the presentations on the event page.

  • Patients_consumers_annual_report

    Annual report on EMA patient and healthcare professional interactions

    EMA has published its 2015 annual report on its interactions with patients, consumers, healthcare professionals and their organisations.The report demonstrates the Agency’s continued commitment to incorporating these stakeholders' views into the regulatory aspect of medicines development.

  • Patients icons and pills

    EMA and FDA reinforce collaboration on patient engagement

    EMA and the United States Food and Drug Administration (FDA) have set up a new cluster on patient engagement. The cluster will provide a forum to share experiences and best practices on the way the two agencies involve patients in development, evaluation and post-authorisation activities related to medicines.

News for patients and carers

Events of interest

  • 30/01/2017 - 31/01/2017

    EMA

    Multi-stakeholder paediatric oncology strategy workshop (cancers with ALK aberrations)

    The aim of the EMA and the ACCELERATE platform's workshop is to review unmet therapeutic needs of children with certain types of cancer and opportunities for targeted paediatric development of innovative anti-cancer medicines. Cancers that are addressed include soft tissue and lymphoid and embryonal neoplasms such as inflammatory myofibroblastic tumour, rhabdomyosarcoma, anaplastic large cell lymphoma and neuroblastoma. Important biological aberrations such as of the anaplastic lymphoma kinase (ALK) occur across these diverse cancers, albeit in small numbers of patients, and represent challenges to address the therapeutic needs of affect paediatric patients. The workshop convenes stakeholders from patient organisations, academia, pharmaceutical industry and regulators. ... Read more

  • 14/11/2016 - 15/11/2016

    EMA

    Workshop on identifying opportunities for ‘big data’ in medicines development and regulatory science

    Rapid developments in technology have led to the generation of vast volumes of data, which have the capability to transform the way the benefit-risk of medicinal products is assessed over their entire life cycle. However, it is recognised there are multiple challenges in the exploitation of these data. These range from the fundamental need to establish methods to enable the access to, integration and analysis of heterogeneous datasets to understanding the limitations in its use. Importantly, robust and transparent mechanisms to protect patient confidentiality are key to secure patient trust. It is important for the European Medicines Agency and the European Union medicines regulatory network to gather information on the latest developments in big data from the perspective of all stakeholders in order to identity how and when the multitude of data sources may contribute to medicinal product development, authorisation and post-marketing surveillance. ... Read more

  • 20/09/2016

    EMA

    European Medicines Agency Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) joint meeting

    This joint PCWP/HCPWP meeting includes the election of the PCWP and HCPWP co-chairs for the 2016 – 2019 mandate. Personalised medicines are discussed and participants are updated on the PCWP/HCPWP topic groups; the 2017 work programme; the framework of collaboration with academia; and feedback is given from the scientific committees. ... Read more

  • 29/11/2016

    EMA

    Training session for patients and consumers interested in EMA activities

    This one-day training session for representatives of patients' and consumers' organisations aims at presenting an overview of medicines evaluation with specific emphasis on where and how they can be involved. Using a hands-on interactive approach, participants will learn more about how they can contribute to scientific advice procedures, Scientific Advisory Group (SAG) meetings and in review of information for patients. ... Read more

  • 05/12/2016 - 06/12/2016

    EMA

    Workshop on measuring the impact of pharmacovigilance activities

    In January 2016 the Pharmacovigilance Risk Assessment Committee (PRAC) adopted a strategy for measuring the impact of pharmacovigilance activities performed at European Union (EU) and Member States level which relies on a collaborative approach of all stakeholders. Measuring the impact of key pharmacovigilance activities will allow regulators and stakeholders to determine which activities are most successful and to identify enablers and barriers for generating positive health impacts which will contribute to the further development of proactive pharmacovigilance systems and to promote best practice across the EU. The aim of this workshop is to facilitate the implementation of the PRAC strategy with a particular focus on the development of methodologies and the fostering of collaboration. ... Read more

  • See all Events of interest

Information for:

Find information for...

FAQ spotlight